Zimbabwe has turned down a significant American health deal valued at $367m (272 million pounds) spanning five years due to the United States' request for confidential information.
This move was revealed following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesman has since stated that the US was requesting health data for scientific study and profit but refused to share the resulting advantages from any future medical innovations.
"We must now begin the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more dialogue to secure a deal acceptable to both sides so the country's vital HIV programme can continue.
Broader Background
This rejection follows a similar case in Kenya, where a court halted a similar health funding agreement following legal challenges were filed about the security of citizens' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to boost transparency and accountability.
According to reports, 16 nations in Africa have to date agreed to these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any equivalent assurance of access to any medical innovations – such as new medicines or tests – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for medical research with no assurance that the end products would be available to our citizens if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one deals were upending structures already established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to ensure that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We welcome further dialogue with our US partners on how subsequent collaboration could be structured in a manner that respects the independence and dignity of each country."
Medical Community Reaction
A leading public health body expressed it acknowledged the government's concerns, but suggested that negotiations must proceed considering a large portion of the nation's HIV programmes were funded by foreign aid.
"If technical issues exist, including those involving information security or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
This impasse highlights the ongoing debate between receiving crucial international aid and protecting a country's data in an increasingly interconnected world.